• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia
    • Books
    • eBooks
    • ABPN SA Courses
    • Social Work Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
    • Psychiatry News Videos
    • Medication Guide Videos
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • FAQs
  • Med Fact Book App
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Misuse of Legally Available Substances in Adolescents and Teens
CLINICAL UPDATE

Misuse of Legally Available Substances in Adolescents and Teens

January 30, 2023
Deepti Anbarasan, MD and Eric Whitney, MD, MSEd
From The Carlat Child Psychiatry Report
Issue Links: Editorial Information | PDF of Issue

Eric Whitney, MD, MSEd. Clinical Instructor, Child and Adolescent Psychiatry Fellow, NYU Grossman School of Medicine. New York, NY.

Deepti Anbarasan, MD. Associate Professor, Psychiatry & Neurology, New York University. New York, NY.

Dr. Whitney and Dr. Anbarasan have no financial relationships with companies related to this material.

Some teens view over-the-counter (OTC) substances as safe or non-addictive (Levine DA, Curr Opin Pediatr 2007;19(3):270–274). In 2020, the National Institute on Drug Abuse reported that 3.2%–4.6% of high schoolers nationwide reported misusing OTC cough and cold medicines in the prior year (www.tinyurl.com/mwpke3js). Below, we will review several commonly misused, legally available substances.

Dextromethorphan

Dextromethorphan (DXM) is the active ingredient in hundreds of OTC cough and cold products, including Coricidin HBP, Robitussin DM, and Delsym, and combined with bupropion in a recently released antidepressant with purportedly rapid effect. Adolescents misuse this drug for its euphoric, stimulant, and dissociative effects. DXM is metabolized by CYP2D6 with a half-life of two to four hours, and its psychoactive properties are based on dosing. In adults, it works as a cough suppressant at doses of 15–30 mg. At 100–200 mg, DXM has a stimulant-like effect, while doses over 200 mg produce intoxication with slurred speech, hallucinations, and impaired memory (Levine, 2007).

DXM toxicity causes various symptoms depending on dose, from flushed skin and tachycardia to hallucinations, ataxic gait, and agitation (Boyer EW, Pediatr Emerg Care 2004;20(12):858–863).

Chronic use of DXM is associated with psychosis and cognitive impairment. Cessation of DXM in chronic users causes non-life-threatening withdrawal symptoms: restlessness, insomnia, muscle aches, dysphoria, and intense cravings (Boyer, 2004). Patients on serotonergic medications who also use DXM are at risk for developing serotonin syndrome.

The US began efforts to curb adolescent misuse of DXM in 2021. Today, 21 state governments prohibit the sales of DXM to those under 18 years old.

Antihistamines

First-generation antihistamines are usually used to treat allergy symptoms (eg, runny nose, sneezing) or motion sickness. Commonly misused agents that cross the blood-brain barrier include diphenhydramine (Benadryl), doxylamine (found in NyQuil), and dimenhydrinate (Dramamine). Adolescents use antihistamines in low doses for sedating and anxiolytic effects, or in higher doses for stimulant-like effects.

Antihistamine toxicity causes symptoms such as delirium, hallucinations, seizures, psychosis, tachycardia, dry mouth, blurry vision, constipation, and urinary retention. Use of antihistamines also causes QT prolongation, increasing the risk of dangerous arrhythmias (www.tinyurl.com/ymrdahvh). Withdrawal symptoms after chronic use include cravings, runny nose, nausea, diarrhea, cramping, irritability, restlessness, and insomnia.

The 2020 “Benadryl Challenge” dared people to ingest large amounts of diphenhydramine and post their experiences on the social media platform TikTok. This coincided with increased diphenhydramine-related emergency department visits in adolescents, including one reported death, followed by a warning from the US Food and Drug Administration (www.tinyurl.com/3sw5xz7p). To date, no laws limit access to antihistamines.

Pseudoephedrine

Pseudoephedrine is a nasal decongestant often packaged with antihistamines, DXM, acetaminophen, or NSAIDs (eg, Sudafed, Comtrex, Dristan, Entex). Usual daily pseudoephedrine doses are 15–60 mg in immediate-release form and 120–240 mg in extended-release form.

Teens misuse pseudoephedrine for its stimulant properties, hoping to boost athletic and academic performance while suppressing appetite and sleep. Toxic effects include hypertension, tachycardia, dizziness, seizures, and psychotic symptoms (Gunn VL et al, Pediatrics 2001;108(3):e52). Withdrawal symptoms include dysphoria, restlessness, and abnormal perception (Schifano F et al, Front Psychiatry 2021;12:657397).

Pseudoephedrine interacts with monoamine oxidase inhibitors (MAOIs) such as selegiline and can induce a hypertensive crisis. Counsel your patients on MAOIs about the risks of hypertensive crisis and the interaction between MAOIs and pseudoephedrine.

Federal law limits daily sales of pseudoephedrine to 3.5 g and monthly sales to 9 g per person. Iowa, Mississippi, and Oregon have age restrictions for purchasing pseudoephedrine.

Kratom

Kratom is an herbal extract from Mitragyna speciosa and acts on opioid receptors. It is sold as a tea, capsule, or powder in vape shops or via the internet. Sales of kratom exceeded $1.13 billion in 2016. Most toxic exposures to kratom in 2011–2017 were among adolescents (Eldridge W, J Pediatr Pediatr Med 2019;3(1):1–5; Sharma V et al, J Adolesc Health 2021;70(4):677–681).

Kratom causes stimulant effects at low doses and euphoria at higher ones. Toxicity causes tachycardia, hypertension, altered mental status, abdominal pain, and seizures. Regular use can create dependence and withdrawal symptoms similar to opioids (anxiety, gastrointestinal symptoms, headache, runny nose, watery eyes, and sweating). Withdrawal can be treated in the same way as opioid withdrawal.

Kratom is illegal in Alabama, Arkansas, and Indiana as well as some cities, such as San Diego and Sarasota. Most states do not regulate it. Advocacy groups and policymakers have stymied efforts to regulate kratom, arguing that it may be beneficial for managing pain and reducing opioid addiction.

Tianeptine

Tianeptine is a tricyclic antidepressant that binds to opioid receptors. It is prescribed outside of the US but sold as a supplement in the US without restrictions. It produces euphoria and is energizing but has rapid withdrawal symptoms similar to opioids.

Tianeptine is banned in Alabama, Georgia, Indiana, Michigan, Minnesota, and Tennessee.

Talking with teens and parents

Here are some recommendations for discussing substance use with patients and families:

  1. Review slang terms for substances, but don’t count on precision. Some kids call pseudoephedrine “meth,” and any street drug might contain deadly fentanyl (see table “Slang Terms for Legal Substances”).
  2. Interview parents and adolescent patients separately.
  3. Ask patients about their use of legally available substances.
  4. Ask patients and families about substance use in peers and their ability to access substances at home and in the community.
  5. Ask parents about unusual medicinal smells or empty medicine containers in the patient’s room.
  6. Counsel families on safe storage techniques and monitoring substances in the home. Advise families to keep medications locked in storage away from children and regularly inventory all medications. Families should safely dispose of any expired or unused medications (www.tinyurl.com/ytyr77ab).

Treatment

Since there is little research on treating misuse of legal substances, we recommend general approaches like motivational interviewing and cognitive behavioral therapy (www.tinyurl.com/yc3ekdb4).

CARLAT VERDICT

Ask about use of legal substances. Intoxication with any of these can lead to dangerous side effects requiring scute management. Counsel teens about the dangers of using legal substances. While the evidence base is sparse, psycho-therapy and behavioral approaches can be useful in treatment. 

CCPR_JanFebMar_2023_Whitney-Anbarasan_Table_slang_thumb.PNGTable: Slang Terms for Legal Substances
For a full PDF of the table, click here

 

Child Psychiatry Clinical Update
KEYWORDS over-the-counter medications psychogenic effects side effects and risks Substance use disorders
    Deepti Anbarasan, MD

    How Do We Help Depressed Smokers Quit?

    More from this author
    Eric Whitney, MD, MSEd

    More from this author
    www.thecarlatreport.com
    Issue Date: January 27, 2023
    SUBSCRIBE NOW
    Table Of Contents
    Learning Objectives, Trauma in Children and Adolescents, CCPR, Jan/Feb/March 2023
    Misuse of Legally Available Substances in Adolescents and Teens
    Recognizing Developmental Trauma Disorder in Children and Adolescents
    Callous Unemotional Traits
    Assessment of Non-Suicidal Self-Injury in Children and Adolescents
    CME Post-Test, Trauma in Children and Adolescents, CCPR, Jan/Feb/Mar 2023
    DOWNLOAD NOW
    Featured Book
    • PB4e_Cover2.png

      Psychiatry Practice Boosters, Fourth Edition (2023)

      Teaches you the key points of 63 of the most clinically relevant studies in psychiatry.
      READ MORE
    Featured Video
    • KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg
      General Psychiatry

      KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

      Read More
    Featured Podcast
    • shutterstock_2622607431.jpg
      General Psychiatry

      Should You Test MTHFR?

      MTHFR is a...
      Listen now
    Recommended
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png

    About

    • About Us
    • CME Center
    • FAQ
    • Contact Us

    Shop Online

    • Newsletters
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN Self-Assessment Courses

    Newsletters

    • The Carlat Psychiatry Report
    • The Carlat Child Psychiatry Report
    • The Carlat Addiction Treatment Report
    • The Carlat Hospital Psychiatry Report
    • The Carlat Geriatric Psychiatry Report
    • The Carlat Psychotherapy Report

    Contact

    carlat@thecarlatreport.com

    866-348-9279

    PO Box 626, Newburyport MA 01950

    Follow Us

    Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

    © 2025 Carlat Publishing, LLC and Affiliates, All Rights Reserved.